Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.05M | 4.57M | 2.40M | 1.16M | 1.70M |
Gross Profit | 1.54M | 4.57M | 2.06M | 1.16M | 1.70M |
EBITDA | -10.15M | -8.39M | -10.06M | -6.27M | -3.26M |
Net Income | -10.24M | -8.55M | -9.26M | -6.17M | -2.75M |
Balance Sheet | |||||
Total Assets | 8.72M | 15.38M | 21.77M | 20.92M | 4.28M |
Cash, Cash Equivalents and Short-Term Investments | 3.26M | 6.75M | 12.81M | 18.32M | 2.90M |
Total Debt | 232.00K | 338.00K | 288.00K | 231.00K | 2.00M |
Total Liabilities | 3.37M | 5.85M | 4.31M | 2.37M | 3.51M |
Stockholders Equity | 5.35M | 9.53M | 17.45M | 18.55M | 773.79K |
Cash Flow | |||||
Free Cash Flow | -9.18M | -5.99M | -11.13M | -5.52M | -1.91M |
Operating Cash Flow | -9.15M | -5.84M | -10.78M | -5.45M | -1.86M |
Investing Cash Flow | 1.72M | 6.52M | -7.99M | -68.00K | -49.32K |
Financing Cash Flow | 5.65M | -180.00K | 5.16M | 20.93M | 1.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | £21.33M | ― | -137.62% | ― | 10.50% | -9.60% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
― | £10.34M | ― | ― | ― | ― | ||
― | £11.62M | ― | -20.90% | ― | ― | ― | |
47 Neutral | £23.02M | ― | -87.30% | ― | ― | 71.17% | |
― | £7.20M | ― | -302.41% | ― | ― | ― | |
67 Neutral | £26.36M | ― | -2.91% | ― | -5.33% | 60.20% |
Arecor Therapeutics has formed a new Scientific Advisory Board composed of world-renowned experts in oral drug delivery and peptide therapeutics. This board will provide crucial technical and strategic guidance as Arecor aims to develop a novel technology platform for the oral delivery of peptides, which could significantly improve bioavailability and address patient needs in markets like diabetes and obesity. The initiative underscores Arecor’s commitment to advancing oral peptide delivery, a challenge that has persisted for decades, with the potential to enhance patient compliance and reduce healthcare burdens.
Arecor Therapeutics plc announced the grant of 295,000 options under its Long Term Incentive Plan and 239,600 options under its All Employee Share Ownership Plan. These options are part of the company’s strategy to incentivize its leadership and employees, with performance conditions tied to time and share price outperformance. This move is likely to strengthen employee commitment and align their interests with the company’s long-term growth objectives.
Arecor Therapeutics plc announced the successful passage of all resolutions at its Annual General Meeting, with one resolution deemed redundant and bypassed. This outcome reinforces the company’s governance and operational strategies, potentially strengthening its position in the biopharmaceutical industry and providing reassurance to stakeholders.
Arecor Therapeutics plc announced the retirement of Dr. Alan E Smith from his role as a Non-Executive Director after over 17 years of service. Dr. Smith’s scientific and strategic guidance has been pivotal in advancing Arecor from its early stages to a clinical-stage company. His departure marks a significant change in the board, but the company remains confident in its future success as it continues to develop its promising pipeline of therapeutics.
Arecor Therapeutics plc announced that key executives, including Chair Andrew Richards, CEO Sarah Howell, and CSO Jan Jezek, have purchased ordinary shares in the company. This move signifies confidence in the company’s future prospects and may positively influence stakeholder perceptions, potentially strengthening Arecor’s position in the biopharmaceutical industry.
Arecor Therapeutics has partnered with Skye Bioscience to develop an enhanced formulation of nimacimab, a CB1 inhibitor for obesity treatment, using Arecor’s Arestat™ technology. This collaboration underscores Arecor’s strategic focus on innovative medicine development and offers significant potential for future licensing opportunities, while addressing unmet needs in metabolic disease treatment.
Arecor Therapeutics plc announced that Andrew Richards, the Chair of the company, has purchased 35,000 ordinary shares at £0.4125 each, increasing his total beneficial interest to 286,611 shares, which represents 0.76% of the total voting rights. This transaction reflects a significant vote of confidence in the company’s future prospects and may positively influence stakeholder perceptions and market positioning.
Arecor Therapeutics plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 2, 2025. This announcement provides shareholders with updated financial information and strategic insights, potentially impacting investor confidence and the company’s market positioning.